Immunocan Secures RMB250 Million Series A Funding to Accelerate Gene-Edited Animal Platforms and AI-Driven Antibody Discovery
Shanghai-based Immunocan, a burgeoning biopharmaceutical company at the forefront of antibody discovery and gene-editing technologies, has successfully closed a RMB250 million (approximately $34.5 million USD) Series A funding round. This…
Rebellions.ai Secures Additional $400 Million Funding, Pushing Valuation to $2.34 Billion Ahead of Planned IPO and Global Expansion
Fresh off a successful Series C funding round in November, South Korean fabless AI chip startup Rebellions has announced an additional $400 million funding infusion, bringing its total capital raised…







